The FDA database lists a supplement dated 29 September 2026 to a generic clozapine application held by Aurobindo Pharma (ANDA206433). The record gives only the applicant, product and date; it does not say what the supplement changed, whether the label was altered, or whether any safety information is involved.
Supplements to generic applications cover many routine matters, such as manufacturing or labelling updates, so this entry alone should not change prescribing. For clozapine the established monitoring requirements, including blood counts, still apply. If the manufacturer's label for the product you dispense is updated, check it for any change.
- Do not change clozapine prescribing on the basis of this listing alone.
- Continue absolute neutrophil count monitoring as set out in your local protocol.
- Check the current label for the brand you dispense if your pharmacy notifies you of a change.
Why it matters
It is a reminder to watch for label updates, not evidence of a new risk.
Don't overread it
A supplement to a generic application is administrative information; it is not a safety communication or a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free